BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 14, 2002
View Archived Issues
Orally bioavailable cathepsin inhibitors designed at Naeja
Read More
New growth hormone secretagogues claimed by Lilly
Read More
Vasopressin/oxytocin antagonists and their use in preterm labor, etc.
Read More
AstraZeneca presents novel antiarrhythmic agents
Read More
Schering describes histamine H3 antagonists for use in allergic rhinitis
Read More
Cytokine production inhibitors designed by Ortho-McNeil
Read More
Novel proton pump inhibitor prodrugs prepared and tested at Takeda
Read More
MacroGenics acquires Eliance, forms alliance with UT Southwestern
Read More
Abgenix and U3 Pharma collaborate to develop therapeutic antibodies for cancer
Read More
Phase II results announced for Ciprofloxacin GR
Read More
New antiepileptic agent with excellent safety profile identified at AWD
Read More
Novo Nordisk presents structurally novel DPP-IV inhibitor
Read More
New class of DNA-targeting antifungal agents in development at Genelabs
Read More
Approaches to design of clinically useful 5-HT6 antagonists discussed by GSK
Read More
AstraZeneca introduces new breast cancer therapy in first market
Read More
RWJ-67657 inhibits proinflammatory mediators in stimulated rheumatoid synovial fibroblasts
Read More
SMP-114 exerts beneficial effects on both inflammation and bone destruction in arthritis model
Read More
Phase IIb trial demonstrates clinical activity and good safety for CTLA4Ig in RA
Read More
Good safety profile reported for TZT-1027 in clinical trial in NSCLC
Read More
Imidacrine prevents cytokinesis and induces cell death after G2 arrest
Read More
Potential use of IP6 as a novel anticancer drug with antiangiogenic and cytotoxic properties
Read More
NicVAX enters phase I testing
Read More
Product R cleared for Israeli phase I study in leukemia and lymphoma
Read More
G17DT plus chemotherapy gives encouraging results in metastatic stomach cancer
Read More
Cipralex now available for prescription in three European markets
Read More
Complete response letter issued for Amevive in psoriasis
Read More
Vertex advances VX-702 into phase I
Read More